Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRUSTY second-line treatment study in metastatic colorectal cancer
jRCTs031180122Phase 3Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab, trifluridine + tipiracil, irinotecan, fluorouracil, tegafur and 1 more in colorectal cancer (CRC) (2 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: Overall survival. Started Oct 2017; status: completed.
02
Drugs
bevacizumabtrifluridine + tipiracilirinotecanfluorouraciltegafur
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on jRCTs031180122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180122.